Greg Tourangeau News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Greg tourangeau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Greg Tourangeau Today - Breaking & Trending Today

Fulcrum Therapeutics, Inc. Forecasted to Post FY2024 Earnings of ($0.78) Per Share (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Fulcrum Therapeutics in a note issued to investors on Monday, May 20th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.78) per share for the year. Cantor Fitzgerald currently has a […] ....

United States , Piper Sandler , Greg Tourangeau , Goldman Sachs Group , Capital Management , Royal Bank , Fulcrum Therapeutics Company Profile , Cantor Fitzgerald , Fulcrum Therapeutics Inc , Fulcrum Therapeutics , Free Report , Fulcrum Therapeutic , Get Free Report , Point Capital , Fulcrum Therapeutics Daily ,

Fulcrum Therapeutics Sees Unusually Large Options Volume (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors bought 9,544 call options on the company. This represents an increase of approximately 867% compared to the typical volume of 987 call options. Fulcrum Therapeutics Stock Down 0.8 % FULC stock opened at $7.64 on […] ....

United States , Piper Sandler , Greg Tourangeau , Sg Americas Securities , Fulcrum Therapeutics Inc , Vanguard Group Inc , Fulcrum Therapeutics Company Profile , Cantor Fitzgerald , Mirae Asset Global Investments Co , Securities Exchange Commission , Royal Bank , Fulcrum Therapeutics , Get Free Report , Therapeutics Stock Down , Exchange Commission , Street Group , Point Capital , Mirae Asset Global Investments , Fulcrum Therapeutics Daily ,

Investors Purchase High Volume of Fulcrum Therapeutics Call Options (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders bought 9,544 call options on the stock. This represents an increase of 867% compared to the average daily volume of 987 call options. Insider Buying and Selling In other Fulcrum Therapeutics news, VP Greg Tourangeau […] ....

United States , Greg Tourangeau , Goldman Sachs Group , Fulcrum Therapeutics Inc , Royal Bank , Cantor Fitzgerald , China Universal Asset Management Co , Sg Americas Securities , Fulcrum Therapeutics Company Profile , Capstone Investment Advisors , Brown Wealth Management , Fulcrum Therapeutics , Get Free Report , Universal Asset Management , Investment Advisors , Wealth Management , Therapeutics Trading Down , Fulcrum Therapeutics Daily ,

Leerink Partnrs Analysts Boost Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Leerink Partnrs upped their Q2 2024 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report released on Monday, May 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.74 for the quarter, up from their […] ....

United States , Piper Sandler , Leerink Partnrs , Greg Tourangeau , Goldman Sachs Group , Vanguard Group Inc , Royal Bank , Capstone Investment Advisors , Sg Americas Securities , Fulcrum Therapeutics Inc , China Universal Asset Management Co , Securities Exchange Commission , Fulcrum Therapeutics Company Profile , Brown Wealth Management , Fulcrum Therapeutics , Free Report , Fulcrum Therapeutic , Get Free Report , Therapeutics Trading Down , Exchange Commission , Universal Asset Management , Investment Advisors , Fulcrum Therapeutics Daily ,

HC Wainwright Equities Analysts Reduce Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Research analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.43) per share for the quarter, down from […] ....

United States , Piper Sandler , Greg Tourangeau , Securities Exchange Commission , Fulcrum Therapeutics Inc , China Universal Asset Management Co , Capstone Investment Advisors , Brown Wealth Management , Royal Bank , Sg Americas Securities , Goldman Sachs Group , Fulcrum Therapeutics , Free Report , Fulcrum Therapeutic , Get Free Report , Exchange Commission , Universal Asset Management , Investment Advisors , Wealth Management , Fulcrum Therapeutics Daily ,